-
-
Erythromycin use is associated with a 2-fold increased risk of sudden cardiac death and a 5-fold increase in those who concurrently receive other medications that significantly inhibit its metabolism by CYP3A4.
-
Rifaximin (Xifaxan) has rreceived US FDA approval on May 25, 2004, for the treatment of travelers diarrhea caused by enteropathogenic (non-invasive) Eschericiha coli in individuals at least 12 years of age. Rifaximin is a rifamycin that is poorly absorbed (< 0.4%) from the gastrointestinal tract, and thus achieves very high concentrations in the feces.
-
Five days of oral treatment with azithromycin appeared to be at least as effective as a similar duration of treatment of treatment with ceftriaxone in children in Cairo with typhoid fever.
-
Sources of funding for pharmaceutical research has come under scrutiny in the last decade as academic and government sources of funding have become increasingly scarce and the pharmaceutical industry has become the main source of research dollars. But the issue of objectivity has been raised, and some have even suggested that negative studies, that is studies that show a drug in an unfavorable light, may never be published. The American Medical Association has recently tackled this issue and has asked the department of Health and Human Services to establish a public registry of all clinical trials in United States.
-
End-stage renal disease is a devastating condition that, according to the United States Renal Data System, plagued approximately 406,000 individuals in the United States in 2001 and is projected to increase to a prevalence of approximately 725,000 by 2010. Furthermore, it is a major public health issue, given the overall poor outcomes and high costs for this chronic condition.
-
Dietary calcium, phytate, and fluid intake are associated with a decreased risk of symptomatic nephrolithiasis in younger women.
-
The present results on the Cache County study provide some of the strongest evidence to date that intake of antioxidant vitamin supplements may be beneficial.
-
The FDA has approved an injectable drug for treating Parkinsons patients during hypomobility periods known as off periods.
-
Glucose Metabolism and Coronary Heart Disease in Patients with Normal Glucose Tolerance; Evidence of Airborne Transmission of the Severe Acute Respiratory Syndrome Virus; Alcohol Intake and Risk of Incident Gout in Men: A Prospective Study
